Neurochase

Executive Summary

Neurochase is a London-based biotechnology company developing a next-generation targeted delivery platform for central nervous system (CNS) therapeutics. Founded in 2019, the company addresses a critical bottleneck in neurological disease treatment: the inability of most drugs, including promising gene therapies, to effectively cross the blood-brain barrier. Neurochase's platform aims to enable precise delivery of therapeutic agents to specific brain regions, potentially transforming the treatment landscape for conditions such as Huntington's, Parkinson's, and Alzheimer's diseases. By improving the biodistribution and efficacy of CNS drugs, Neurochase could unlock the curative potential of gene therapies that have historically failed in clinical trials due to delivery limitations, not lack of therapeutic effect. Currently in Phase 2 development, Neurochase is poised to generate pivotal clinical data that could validate its platform's safety and efficiency. The company operates in a high-demand niche within the CNS drug delivery market, which is experiencing rapid growth due to the aging global population and increasing prevalence of neurological disorders. While still private and early-stage, Neurochase's focused strategy and UK biotech ecosystem support position it as a potential leader in CNS delivery. Key upcoming catalysts include clinical trial milestones, potential strategic partnerships, and financing rounds to advance its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Clinical Data Readout35% success
• Q2 2027Strategic Partnership for Platform Licensing40% success
• Q3 2026Series B Financing Round70% success